文献速递乳腺技术与安全MR

初始MRI表现可预测HER2阳性乳腺癌新辅助治疗病理完全缓解

Initial MRI findings predictive of a pathological complete response to neoadjuvant treatments in HER2-positive breast cancers.
PubMed 文献 · Eur J Radiol · 2024-07-14

回顾性纳入中心1的111例和中心2的71例接受新辅助系统治疗的HER2阳性乳腺癌患者,分析初始临床病理及MRI表现与病理完全缓解(乳腺及淋巴结无浸润性恶性细胞)的关系。初始MRI上存在可疑伴随非肿块强化是唯一显著预测病理完全缓解的参数(中心1 P<0.001,中心2 P=0.04),观察者间一致性良好(组内相关系数0.872,95%CI 0.73-1.00)。

要点

  • 初始MRI显示可疑伴随非肿块强化与HER2阳性乳腺癌新辅助治疗后病理完全缓解相关。
  • 该征象观察者间一致性良好,组内相关系数0.872(95%CI 0.73-1.00)。
  • 中心1病理完全缓解率46%(51例)高于中心2的23%(16例),两中心差异有统计学意义(P=0.003)。

核心结论

  • HER2阳性乳腺癌初始MRI上存在可疑伴随非肿块强化可预测新辅助系统治疗后达到病理完全缓解,作者认为这一初步发现需通过前瞻性多中心研究确认。

研究设计与样本

  • 回顾性研究,训练集为中心1的111例、验证集为中心2的71例接受新辅助系统治疗的HER2阳性乳腺癌患者,记录初始临床病理数据与MRI表现,病理完全缓解定义为乳腺及淋巴结无浸润性恶性细胞;对50例MR研究评估非肿块强化参数的观察者间一致性(组内相关系数)。

关键影像表现/征象

  • 初始MRI上存在可疑伴随非肿块强化是唯一显著预测病理完全缓解的参数(中心1 P<0.001,中心2 P=0.04)。
  • 该MRI征象的观察者间一致性良好,组内相关系数为0.872(95%CI 0.73-1.00)。

诊断标准与关键数值

  • 病理完全缓解定义为乳腺及淋巴结中无浸润性恶性细胞。
  • 中心1病理完全缓解51例(46%),中心2病理完全缓解16例(23%),两中心差异有统计学意义(P=0.003)。
  • 两中心在肿瘤浸润淋巴细胞水平及淋巴血管侵犯方面差异有统计学意义(P<0.001)。

局限性

  • 作者指出该显著初步发现需通过前瞻性多中心研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aimed to determine if initial MRI findings could predict a pathological complete response (pCR) following neoadjuvant systemic therapy (NST) in HER2-positive breast cancers.

METHODS: The study retrospectively included 111 patients (Center 1, training set) and 71 patients (Center 2, validation set) with HER2-positive cancer who underwent NST. Initial clinicopathological data and MRI findings were recorded. Continuous variables were analyzed using the Mann-Whitney and Student's t-tests, while categorical variables were analyzed using the χ2 or Fisher's exact test. Univariate analysis was conducted to determine the associations between these variables and pathological complete response (pCR), defined as the absence of invasive malignant cells in the breast and lymph nodes. Interobserver reproducibility was assessed for associated non-mass enhancement (NME) parameter by analyzing 50 MR studies (intraclass correlation coefficient).

RESULTS: pCR was achieved in 67 patients, 51 (46 %) from Center 1 and 16 (23%) from Center 2 (p = 0.003), with significant differences between Centers 1 and 2 in tumor-infiltrating lymphocyte levels and lymphovascular invasion (p < 0.001). The initial presence of suspicious associated NME was the only significant parameter predictive of pCR (p < 0.001 for Center 1 and 0.04 for Center 2). The inter-observer reproducibility for this MRI feature was good, with an intraclass correlation coefficient of 0.872 (95 % CI: 0.73-1.00).

CONCLUSION: The presence of suspicious associated NME in HER2-positive cancers on the initial MRI study was predictive of achieving pCR after NST. This significant preliminary finding warrants confirmation through prospective multicenter studies.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ribrag A, Lissavalid E, Fayard J, et al. Initial MRI findings predictive of a pathological complete response to neoadjuvant treatments in HER2-positive breast cancers. Eur J Radiol. 2024. PMID: 39024664. doi:10.1016/j.ejrad.2024.111625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。